Table of Contents 1. Research Methodology 2. Executive Summary 3. Migraine - An Overview 3.1. Symptoms of migraine 3.2. Stages of Migraine 3.3.Types of Migraine 3.4. Types of migraine on the basis of frequency of occurrence 4. Treatment of Migraine 4.1. Goal of Migraine Treatment 4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological 4.2.1. Pharmacological treatment of migraine 4.2.2. Pharmacological - Abortive 4.2.3. Pharmacological - Preventive 4.2.4. Non-Pharmacological Treatment of Migraine 4.2.5. Non- Pharmacological - Surgical 4.2.6. Non- Pharmacological - Non-Surgical 5. Anti-Migraine Pipeline Drugs Analysis 5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working) 5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1 5.2.1. Description 5.2.2. Regulatory Milestones 5.2.3. Advantages & Disadvantages 5.2.4. Product Profile & Expected Launch 5.2.5. Clinical Trials and Status 5.2.6. Pivotal Clinical Trials and Results 5.2.7. Drug X-1- Global Market Potential 5.2.8. Drug X-1- 7Ps Analysis 5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2 5.3.1. Description 5.3.2. Regulatory Milestones 5.3.3. Advantages & Disadvantages 5.3.4. Product Profile & Expected Launch 5.3.5. Clinical Trials and Status 5.3.6. Pivotal Clinical Trials and Results 5.3.7. Drug - X2 - Global Market Potential 5.3.8. Drug - X2 - 7Ps Analysis 5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs) 5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug 5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3 5.6.1. Description 5.6.2. Regulatory Milestones 5.6.3. Advantages & Disadvantages 5.6.4. Product Profile & Expected Launch 5.6.5. Clinical Trials and Status 5.6.6. Pivotal Clinical Trials and Results 5.6.7. Drug - X3 - Global Market Potential 5.6.8. Drug - X3 - 7Ps Analysis 5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4 5.7.1. Description 5.7.2. Regulatory Milestones 5.7.3. Advantages & Disadvantages 5.7.4. Product Profile & Expected Launch 5.7.5. Clinical Trials and Status 5.7.6. Pivotal Clinical Trials and Results 5.7.7. Drug - X4 - Global Market Potential 5.7.8. Drug - X4 - 7Ps Analysis 5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5 5.8.1. Description 5.8.2. Regulatory Milestones 5.8.3. Advantages & Disadvantages 5.8.4. Product Profile & Expected Launch 5.8.5. Clinical Trials and Status 5.8.6. Pivotal Clinical Trials and Results 5.8.7. Drug - X5 - Global Market Potential 5.8.8. Drug - X5 - 7Ps Analysis 5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6 5.9.1. Description 5.9.2. Regulatory Milestones 5.9.3. Advantages & Disadvantages 5.9.4. Product Profile & Expected Launch 5.9.5. Clinical Trials and Status 5.9.6. Pivotal Clinical Trials and Results 5.9.7. Drug - X6 - Global Market Potential 5.9.8. Drug - X6 - 7Ps Analysis 5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7 5.10.1. Description 5.10.2. Regulatory Milestones 5.10.3. Advantages & Disadvantages 5.10.4. Product Profile & Expected Launch 5.10.5. Clinical Trials and Status 5.10.6. Pivotal Clinical Trials and Results 5.10.7. Drug - X7 - Global Market Potential 5.10.8. Drug - X7 - 7Ps Analysis 6. Global Migraine Drugs Market: Growth and Forecast 6.1. By Value (2012-2016) 6.2. By Value (2017-2022) 7. Global Migraine Drugs Market - Analysis By Type 7.1. Global Migraine Drugs Market, By Type: Breakdown (%) 7.1.1. Global Migraine Drugs Market- By Type: 2016 (%) 7.1.2. Global Migraine Drugs Market By Type: 2022 (%) 7.2. Global Migraine Drugs Market- By Acute 7.2.1. By Value (2012-2016) 7.2.2. By Value (2017-2022) 7.3. Global Migraine Drugs Market- By Prophylaxis 7.3.1. By Value (2012-2016) 7.3.2. By Value (2017-2022) 8. Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW) 8.1. U.S. Migraine Drugs Market, By Value (2012-2022) 8.2. U.K. Migraine Drugs Market, By Value (2012-2022) 8.3. Japan Migraine Drugs Market, By Value (2012-2022) 8.4. France Migraine Drugs Market, By Value (2012-2022) 8.5. Italy Migraine Drugs Market, By Value (2012-2022) 8.6. Germany Migraine Drugs Market, By Value (2012-2022) 8.7. ROW Migraine Drugs Market, By Value (2012-2022) 9. Market Dynamics 9.1. Migraine Drug Market Drivers 9.2. Migraine Drug Market Challenges 10. Company Profiles 10.1. Amgen 10.2. Allergan 10.3. Eli Lilly 10.4. Alder Pharmaceuticals 10.5. Teva Pharmaceuticals 10.6. Vernalis 10.7. Pfizer 10.8. Impax Laboratories 10.9. Glaxo Smithkline

List of Figures Figure 1: 2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1st pivotal trial) Figure 2: Improvement at two hours in people who took LEVADEX compared to Placebo (2nd pivotal trial) Figure 3: Global Drug - X1 Market Size, By Value, Forecast, 2019-2022 (USD Billion) Figure 4: Percentage of patients achieving primary end point Figure 5: Percentage of patients achieving secondary endpoint Figure 6: Global Drug - X2 Market Size, By Value, Forecast, 2019-2022 (USD Million) Figure 7: Efficacy in 2 hour pain freedom Figure 8: Global Drug - X3 Market Size, By Value, Forecast, 2019-2022 (USD Billion) Figure 9: Reduction in Monthly migraine days - weeks 1 through 12 Figure 10: Percentage of patients with =75% reduction in number of migraine days - weeks 1 through 24 Figure 11: Percentage of patients with 100% response rate (no migraine in any given month) - months 1 through 6 Figure 12: Global Drug - X4 Market Size, By Value, Forecast, 2019-2022 (USD Million) Figure 13: Global Drug - X5 Market Size, By Value, Forecast, 2019-2022 (USD Million) Figure 14: Global Drug - X6 Market Size, By Value, Forecast, 2019-2022 (USD Million) Figure 15: Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group Figure 16: Reduction in days using acute pain medications in recent drug overuse group Figure 17: Global Drug - X7 Market Size, By Value, Forecast, 2019-2022 (USD Million) Figure 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion) Figure 19: Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion) Figure 20: Global consumption of chocolate confectionary, By volume (in 1000 metric tones) Figure 21: Global Migraine Drugs Market Share, By Type, 2016 (%) Figure 22: Global Migraine Drugs Market Share, By Type, 2022 (%) Figure 23: Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million) Figure 24: Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million) Figure 25: Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million) Figure 26: Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million) Figure 27: U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 28: U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 29: U.S Adult Migraine Patients, In Percentage Figure 30: U.S Migraine Patients, By gender, In Percentage Figure 31: U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 32: U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 33: U.K. Migraine Patient, In Percentage Figure 34: NHS Budget for mental illness, In Billion Figure 35: Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 36: Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 37: Japan Migraine Patient out of total population, In Percentages Figure 38: France Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 39: France Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 40: France Migraine Patient, In Percentage Figure 41: Unemployment rate in France in percentage Figure 42: Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 43: Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 44: Italy Migraine Patient out of total population, In Percentages Figure 45: Italy Unemployment rate, In Percentages Figure 46: Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 47: Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 48: Germany Migraine Patient out of total population, In Percentages Figure 49: First Time asylum application, In Number Figure 50: ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion) Figure 51: ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion) Figure 52: Total global sales of Allergan's Botox in 2016 and forecasted for 2022 (USD Million) List of Tables Table A: Summary of Completed Clinical Trials of Drug - X1 Table B: Summary of Completed & ongoing Clinical Trials of Drug - X1 Table C: Summary of Completed & ongoing Clinical Trials of Drug - X1 Table D: Number and percentage of patients who reported each particular TEAE with safety population for each dose. Table E: Summary of Completed & ongoing Clinical Trials of Drug - X2 Table F: Summary of Completed & ongoing Clinical Trials of Drug - X3 Table G: Summary of Completed Clinical Trials of Drug - X4 Table H: Summary of Ongoing Clinical Trials of Drug - X5 Table I: Summary of Completed & Ongoing Clinical Trials of Drug - X6 Table J: Summary of Completed & Ongoing Clinical Trials of Drug - X7